首頁 › 濾泡性淋巴瘤 › 猶他州 › Salt Lake City
Salt Lake City, UT 的 濾泡性淋巴瘤 臨床試驗
13 項針對 濾泡性淋巴瘤 的研究正在 Salt Lake City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
招募中3 期
- Huntsman Cancer Institute/University of Utah, Salt Lake City
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- Intermountain Healthcare, Salt Lake City
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
招募中3 期
- Research Site, Salt Lake City
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
招募中3 期
- Huntsman Cancer Institute - Oncology Division, Salt Lake City
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
招募中1 期
- Huntsman Cancer Institute/University of Utah, Salt Lake City
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- Huntsman Cancer Insititute, University of Utah, Salt Lake City
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
招募中2 期
- University of Utah, Salt Lake City
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Salt Lake City
其他城市的 濾泡性淋巴瘤 試驗
- New York City, NY24 項研究
- Milwaukee, WI19 項研究
- Nashville, TN18 項研究
- Houston, TX18 項研究
- Boston, MA17 項研究
- Baldwin Park, CA16 項研究
- Seattle, WA15 項研究
- Durham, NC15 項研究
- Columbus, OH13 項研究
- Chicago, IL12 項研究
- San Antonio, TX12 項研究
- Philadelphia, PA12 項研究
Salt Lake City 的其他研究
- 非小細胞肺癌31 項研究
- 癌症（所有類型）27 項研究
- 乳癌27 項研究
- 大腸直腸癌22 項研究
- 肺癌21 項研究
- 黑色素瘤21 項研究
- 多發性骨髓瘤21 項研究
- 轉移性癌症20 項研究
- 卵巢癌19 項研究
- 肥胖症18 項研究
- 急性髓系白血病17 項研究
- 心臟衰竭17 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。